KROS — Keros Therapeutics, Inc.

Ownership history in EDBI Pte Ltd  ·  13 quarters on record

This page tracks every 13F SEC filing in which EDBI Pte Ltd reported a position in Keros Therapeutics, Inc. (KROS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.79% (2024 Q3)
Avg. % of fund
0.44%
First filed
2021 Q4
Last filed
2024 Q4
Quarters held
13
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2024 Q4 UNCHANGED 10,105 — 0% 0.17% $160K $15.83
2024 Q3 UNCHANGED 10,105 — 0% 0.79% $587K $58.07
2024 Q2 UNCHANGED 10,105 — 0% 0.52% $462K $45.70
2024 Q1 UNCHANGED 10,105 — 0% 0.75% $669K $66.20
2023 Q4 UNCHANGED 10,105 — 0% 0.40% $402K $39.76
2023 Q3 UNCHANGED 10,105 — 0% 0.35% $322K $31.88
2023 Q2 UNCHANGED 10,105 — 0% 0.33% $406K $40.18
2023 Q1 UNCHANGED 10,105 — 0% 0.48% $431K $42.70
2022 Q4 UNCHANGED 10,105 — 0% 0.62% $485K $48.02
2022 Q3 UNCHANGED 10,105 — 0% 0.40% $380K $37.62
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    KROS price (monthly, adj. close)

Other funds also holding KROS

As of 2025 Q4 — sorted by position size

Rangeley Capital, LLC 1.64% Madison Avenue Partners, LP 3Y 0.72% ORBIMED ADVISORS LLC 3Y 7Y 0.33% Nantahala Capital Management, LLC 3Y 7Y 0.24% HUSSMAN STRATEGIC ADVISORS, INC. 3Y 7Y 0.21% Quantedge Capital Pte Ltd 3Y 0.19% OXFORD ASSET MANAGEMENT LLP 3Y 7Y 0.18% EJF Capital LP 3Y 7Y 0.17% Nantahala Capital Management, LLC 3Y 7Y 0.17% PDT Partners, LLC 3Y 7Y 0.15%
← Back to EDBI Pte Ltd Holdings